PURPOSE: To develop a population pharmacokinetic (PK) model for HM781-36 (poziotinib) and its metabolites in cancer patients. METHODS: Blood samples were collected from three phase I studies in which fifty-two patients received oral HM781-36B tablets (0.5-32 mg) once daily for 2 weeks, and another 20 patients received oral HM781-36B tablets (12, 16, 18, 24 mg) in fasting (12 patients) or fed (eight patients) state once daily for 4 weeks. Nonlinear mixed effect modeling was employed to develop the population pharmacokinetic model. RESULTS: HM781-36 PK was ascribed to a two-compartment model and HM781-36-M1/-M2 PK to one-compartment model. HM781-36 oral absorption was characterized by first-order input (absorption rate constant: 1.45 ± 0.23 h⁻¹). The central volume of distribution (185 ± 12.7 L) was influenced significantly by body weight. The absorption rate constant was influenced by food. The typical HM781-36 apparent clearance was 34.5 L/h (29.4 %CV), with an apparent peripheral volume of distribution of 164 L (53.5 %CV). Other covariates did not significantly further explain the PKs of HM781-36. CONCLUSIONS: The proposed model suggests that HM781-36 PKs are consistent across most solid tumor types, and that the absorption process of HM781-36 is affected by the fed state before dosing. HM781-36 PKs are not complicated by patient factors, other than body weight.
PURPOSE: To develop a population pharmacokinetic (PK) model for HM781-36 (poziotinib) and its metabolites in cancerpatients. METHODS: Blood samples were collected from three phase I studies in which fifty-two patients received oral HM781-36B tablets (0.5-32 mg) once daily for 2 weeks, and another 20 patients received oral HM781-36B tablets (12, 16, 18, 24 mg) in fasting (12 patients) or fed (eight patients) state once daily for 4 weeks. Nonlinear mixed effect modeling was employed to develop the population pharmacokinetic model. RESULTS:HM781-36 PK was ascribed to a two-compartment model and HM781-36-M1/-M2 PK to one-compartment model. HM781-36 oral absorption was characterized by first-order input (absorption rate constant: 1.45 ± 0.23 h⁻¹). The central volume of distribution (185 ± 12.7 L) was influenced significantly by body weight. The absorption rate constant was influenced by food. The typical HM781-36 apparent clearance was 34.5 L/h (29.4 %CV), with an apparent peripheral volume of distribution of 164 L (53.5 %CV). Other covariates did not significantly further explain the PKs of HM781-36. CONCLUSIONS: The proposed model suggests that HM781-36 PKs are consistent across most solid tumor types, and that the absorption process of HM781-36 is affected by the fed state before dosing. HM781-36 PKs are not complicated by patient factors, other than body weight.
Authors: Jacqulyne P Robichaux; Yasir Y Elamin; Zhi Tan; Brett W Carter; Shuxing Zhang; Shengwu Liu; Shuai Li; Ting Chen; Alissa Poteete; Adriana Estrada-Bernal; Anh T Le; Anna Truini; Monique B Nilsson; Huiying Sun; Emily Roarty; Sarah B Goldberg; Julie R Brahmer; Mehmet Altan; Charles Lu; Vassiliki Papadimitrakopoulou; Katerina Politi; Robert C Doebele; Kwok-Kin Wong; John V Heymach Journal: Nat Med Date: 2018-04-23 Impact factor: 53.440
Authors: Devin G Roller; Stephen A Hoang; Kristopher D Rawls; Katherine A Owen; Michael B Simmers; Robert A Figler; Julia D Wulfkuhle; Emanuel F Petricoin; Brian R Wamhoff; Daniel Gioeli Journal: Sci Rep Date: 2021-03-10 Impact factor: 4.379